Advances in Tumour-Infiltrating Lymphocytes for Triple-Negative Breast Cancer Management

References

• da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC. Triple negative breast cancer: a thorough review of biomarkers. Crit Rev Oncol Hematol. 2020;145:102855. doi:10.1016/j.critrevonc.2019.102855
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. doi:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Won K, Spruck C. Triple-negative breast cancer therapy: current and future perspectives (Review). Int J Oncol. 2020;57(6):1245–1261. doi:10.3892/ijo.2020.5135
   PubMed Web of Science ®Google Scholar
• Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic markers in triple-negative breast cancer. Clin Breast Cancer. 2018;18(5):e841–50. doi:10.1016/j.clbc.2018.07.023
   PubMed Web of Science ®Google Scholar
• Howard FM, Olopade OI. Epidemiology of triple-negative breast cancer. Cancer J. 2021;27(1):8–16. doi:10.1097/PPO.0000000000000500
   PubMed Web of Science ®Google Scholar
• Lyons TG. Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol. 2019;20(11). doi:10.1007/s11864-019-0682-x
   PubMed Web of Science ®Google Scholar
• Zhou Y, Tian Q, Wang BY, Yang J, Zhao SD, Yang J. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Eur Rev Med Pharmacol Sci. 2021;25(7):2885–2897.
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp127
   PubMed Web of Science ®Google Scholar
• Mahmoud SMA, Paish EC, Powe DG, et al. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–1955. doi:10.1200/JCO.2010.30.5037
   PubMed Web of Science ®Google Scholar
• Mouawad R, Spano JP, Khayat D. Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol. 2011;29(15):1935–1936. doi:10.1200/JCO.2011.35.4845
   PubMed Web of Science ®Google Scholar
• Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293(2):247–269. doi:10.1007/s00404-015-3859-y
   PubMed Web of Science ®Google Scholar
• Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–145. doi:10.1016/j.semcancer.2020.06.005
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS One. 2016;11(6):e0157368. doi:10.1371/journal.pone.0157368
   PubMed Web of Science ®Google Scholar
• Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res. 2019;8:1342. doi:10.12688/f1000research.18888.1
   Google Scholar
• Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inste. 2011;103(6):470–477. doi:10.1093/jnci/djr030
   PubMedGoogle Scholar
• Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015;72(2):333–338.
   PubMed Web of Science ®Google Scholar
• Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022; 12:919072.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Schütz F, Stefanovic S, Mayer L, von Au A, Domschke C, Sohn C. PD-1/PD-L1 pathway in breast cancer. Oncol Res Treat. 2017;40(5):294–297. doi:10.1159/000464353
   PubMed Web of Science ®Google Scholar
• Lotfinejad P, Asghari Jafarabadi M, Abdoli Shadbad M, et al. Prognostic role and clinical significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): a Systematic Review and Meta-Analysis Study. Diagnostics. 2020;10(9):704. doi:10.3390/diagnostics10090704
   Web of Science ®Google Scholar
• Loi S, Michiels S, Adams S, et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021;32(10):1236–1244. doi:10.1016/j.annonc.2021.07.007
   PubMed Web of Science ®Google Scholar
• Gupta RK, Roy AM, Gupta A, et al. Systemic therapy de-escalation in early-stage triple-negative breast cancer: dawn of a new era? Cancers. 2022;14(8):1856. doi:10.3390/cancers14081856
   PubMed Web of Science ®Google Scholar
• Schmid P. The use of immunotherapy in triple-negative breast cancer. Clin Adv Hematol Oncol. 2021;19(12):12.
   Web of Science ®Google Scholar
• Carlino F, Diana A, Piccolo A, et al. Immune-based therapy in triple-negative breast cancer: from molecular biology to clinical practice. Cancers. 2022;14(9):2102. doi:10.3390/cancers14092102
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228–241. doi:10.1038/nrclinonc.2015.215
   PubMed Web of Science ®Google Scholar
• Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes. JAMA Oncol. 2016;2(10):1354. doi:10.1001/jamaoncol.2016.1061
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–414. doi:10.1038/nri3845
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111. doi:10.1038/35074122
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.
   PubMed Web of Science ®Google Scholar
• Fan Y, He S. The characteristics of tumor microenvironment in triple negative breast cancer. Cancer Manag Res. 2022;14:1–17. doi:10.2147/CMAR.S316700
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48. doi:10.1186/bcr3148
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Biomarker. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker. Accessed February 8, 2023.
   Google Scholar
• Understanding Prognostic versus Predictive Biomarkers. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Available from: https://www.ncbi.nlm.nih.gov/books/NBK402284/. Accessed February 8, 2023.
   Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international tils working group 2014. Ann Oncol. 2015;26(2):259–271. doi:10.1093/annonc/mdu450
   PubMed Web of Science ®Google Scholar
• Gao G, Wang Z, Qu X, Zhang Z. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):179. doi:10.1186/s12885-020-6668-z
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148(3):467–476. doi:10.1007/s10549-014-3185-2
   PubMed Web of Science ®Google Scholar
• Dieci MV, Tsvetkova V, Orvieto E, et al. Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Res. 2018;20(1):62. doi:10.1186/s13058-018-1003-1
   PubMed Web of Science ®Google Scholar
• de Jong VMT, Wang Y, Opdam M, et al. 159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group. Ann Oncol. 2020;31:S303. doi:10.1016/j.annonc.2020.08.281
   Google Scholar
• Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–2713. doi:10.1038/bjc.2013.634
   PubMed Web of Science ®Google Scholar
• Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1):59. doi:10.1186/s40425-016-0165-6
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory t cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373–5380. doi:10.1200/JCO.2006.05.9584
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two Phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–2966. doi:10.1200/JCO.2013.55.0491
   PubMed Web of Science ®Google Scholar
• Hornychová H, Melichar B, Tomšová M, Mergancová J, Urminská H, Ryška A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 2008;26(10):1024–1031. doi:10.1080/07357900802098165
   PubMed Web of Science ®Google Scholar
• Denkert C et al . (2010). Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. JCO, 28(1), 105–113. 10.1200/JCO.2009.23.7370
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/results?cond=TNBC+-+TripleNegative+Breast+Cancer&term=TIL+&cntry=&state=&city=&dist=. Accessed February 8, 2023.
   Google Scholar